PBAC's latest decision on Fluticasone propionate with salmeterol xinafoate: Not recommended (2016). Considered for Treatment of asthma in adults with frequent episodes despite oral corticosteroids or optimal inhaled corticosteroid doses, and symptomatic treatment of severe COPD (FEV1 <50% predicted) with a history of repeated exacerbations despite regular beta-2 agonist therapy.
PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2007
Submissions
2
2007 → 2016
Eligible population
Adults with asthma who have had frequent episodes while receiving oral corticosteroids or optimal doses of inhaled corticosteroids; patients with severe COPD (FEV1 <50% predicted) with a history of repeated exacerbations despite regular beta-2 agonist therapy.
Therapy area
Respiratory
Line of therapy
Any
Evidence base
Single-arm
Comparator
Seretide Accuhaler 500/50
Economic model
Cost-minimisation
ICER note
Minor submission; cost-minimisation analysis only, no ICER calculated.
Why PBAC said no
Reasons cited in the latest PSD: inability to back titrate the dose with a similar device, different delivery device requiring additional patient training and potentially causing confusion and non-compliance, single high strength presentation limiting suitability for many patients, no clinical need identified
Submission history
Mar 2007: Recommended with restriction · Restricted